Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis
and the resulting fractures cause significant morbidity. Following initiation of oral …

Osteoporosis associated with long-term glucocorticoid therapy remains a common and
serious bone disease. Additionally, in recent years it has become clear that more subtle …

Glucocorticoid‐induced osteoporosis (GIO) is the second most common form of osteoporosis
and is the most common iatrogenic form of the disease. Fractures may occur in 30% to 50 …

The diagnosis of osteoporosis centres on the assessment of bone mineral density (BMD).
Osteoporosis is defined as a BMD 2· 5 SD or more below the average value for …

The introduction of the WHO FRAX® algorithms has facilitated the assessment of fracture
risk on the basis of fracture probability. Its use in fracture risk prediction has strengths, but …

Glucocorticoids are effective immunomodulatory drugs used for many inflammatory
disorders as well as in transplant recipients. However, both iatrogenic and endogenous …

Studies of oral corticosteroid dose and loss of bone mineral density have reported
inconsistent results. In this meta-analysis, we used information from 66 papers on bone …

Glucocorticoid administration is the most common cause of secondary osteoporosis and the
leading cause of nontraumatic osteonecrosis. In patients receiving long-term therapy …

This paper provides a framework for the development of national guidelines for the
management of glucocorticoid-induced osteoporosis in men and women aged 18 years and …

Objective To develop and validate two new fracture risk algorithms (QFractureScores) for
estimating the individual risk of osteoporotic fracture or hip fracture over 10 years. Design …